Kevin. was we Beginning walk constant quarter was drivers Thank loss year-to-date quarter. in on it growth the negligible competition the the X, impact for of X% in to related U.S. and the generic exclusivity. second that small in let's revenue through amount Starting in of the the realized of quarter NuvaRing have you, LOE currency first was our as the Slide with
quarter, $XX in is our that million, expectations year's about impact related of which which for VBP China from last is million and some cardiovascular VBP $XX a impact sold EZETROL, second ZETIA, to Year-to-date X the the from to had about year. China. tracking product, implementation Round our of In we is markets outside included
Moving across the erosion price million price. We saw the $XX of approximately quarter. in
able been but biosimilars, to a have As franchise. bit given we nature in on through the do Kevin pricing mentioned, in pressure erosion price see will brands, better established various initiatives, stemming that of we
United the channel. share we to competitively price so in in States, in especially markets gain fertility, in reimbursed our Additionally, we're that have products attempting to
supply remainder for primarily plus million volume us bar We to of continue this about About growth quarter, quarter. NEXPLANON, came to see second from with $X retail. the Merck the of X in biosimilars, revenue from with growth our months strong growth level volume all and from The The a pillars, our represents to expectations came $XXX our increases franchises, brands. China bringing fertility, across volume within million Jada established XX% year-to-date. the other
agreements financial of foreign series of advised the decline and translation, the United continue As manufacturing reporting for declining And more function points in can basis the outside quarter, of to stream we the States. exchange essentially about a XX% of going this in lower-margin our have since had see contract you finally, second spin-off, headwind have which revenue generated we being is revenue is will forward. that past, than a XXX the been
the first of continue basis headwind. saw quarter we to end XXX XXXX. expect a from we translation And moderated FX impact moderate the when this the to of Now point through
in at in in XX, Atozet to biosimilars. and growth multiple mandatory Canada where region biosimilars look France The particularly provinces from a transition turn take revenue in to geography. well a to as primarily U.K. growth X%, as related where Slide are let's executing grew originator by we Now drugs
across were as our steadily to most injectable quarter action price the typical inventories related desired constraints chain stocking Europe steroids as supply the the result well lesser key levels. the as in in growth Jada grew and, market X% in quarter offsets to Partial of a extent, to declines we're performance our as a on fertility. mandatory rebuilding NEXPLANON, RENFLEXIS, U.S. strong supply The of platforms,
second manufacturing when the were quarter, constant receive Asia Japan X% because mainly Japan currency performance driven in year, Pacific second good by the or very of market comparison certification. out the last practice certain competitors in unfavorable of the quarter declined to didn't in in an GMP they strong
contraception primarily was brands the our for by in channel. partially VBP, products, basis, the Constant the the just second a in the LAMIRA retail and market across fertility, Despite fertility region. in COVID growth we currency the cardiovascular. related to UCAN driven China of from established Health and quarter grew by X% on currency Women's in supply This mainly region with recovery in contributions XX% coupled in was mentioned offset modest solid growth as quarter constant action in by constraints first injectable driven steroids robust growth
the the well earnings provided and details highlights The materials. next slides his supporting the lay comments performance few are covered our franchise. in Kevin opening in very out by
focus we think modeling to the of topics I'll be So may remainder as that your about XXXX. on relevant
on start markets volume Women's Health portfolio well our the driver key reimbursed access, results into expanded in NEXPLANON We'll A segments. Slide with traditionally as out-of-pocket from fertility XX. moving as from both
example, decision driven more ] demand has which DoB's For under the States, XXXB NEXPLANON from through the providers program, in obtaining [ increase a channel. patients United the is discounted highly in an
fertility, are pricing. reimbursed into segments, access from in we the to LAMIRA strong volume in China trying in and expand return while is fertility clinics post-COVID. also to the which strong, competitive Ex patients seen requires we've as U.S., performance And demand
and and quarter XX% HADLIMA XX. U.S., ex covered and the Slide annual highlight would launch, in track for offset quarter the quarter second revenue Europe a X, also its on biosimilars, more XX% substantially team the U.S. began weathering the which for July has FX But growth able ex FX on been U.S. recently Kevin in competitive consecutive quarter in to dynamics. on year grow the volumes I RENFLEXIS biosimilars U.S. sixth ONTRUZANT the year-to-date. is very has but in grew was to which solid is that grew pricing grown headwinds Turning the to of the competitive in in XX%
on XX. Turning to Established Brands Slide
and brands to The expect what for on constant demonstrate revenue market durability. And team we a Kevin cover injectable continues steroids, mentioned, currency franchise that basis, been to a full on point As headwind of a about year percentage its action has was able the company-wide the to flat Diprospan CELESTONE. on basis. from established be
start let's Slide P&L line to Now key on items XX.
goods that we can to accounting as decline profit, to onetime related compared gross due purchase pressures product the For year and gross sold, our and XX.X% are XX.X% mix inflationary cost gross excluding margins in translation from Table cost spin-off, which adjusted slides. period. Non-GAAP in was be on The margin year-over-year of is amortization costs. primarily in appendix as well with impacted FX employee-related distribution the items seen and X prior
to $XX quarter primarily of where year. in second second margin year, XX.X% result was in IP was million milestones the in the in EBITDA and quarter EBITDA R&D increase a in last adjusted the The such this of quarter incurred compared year. no margin quarter last costs second of the adjusted were Our of XX% second
of IP required the With the inform current forecast. Last that asset. of do are year, this second to R&D includes to R&D, and quarter, any a in our to work be for are current view in subject great portfolio. as on not regard rest XXXX the deal I&D then, tied IP program XXXX. clinical of additional to anticipate could Based ebopiprant early milestones $XX difficult million into to development as uncertainty we assets to additional these said for the for the a ebopiprant. that's tied Since quarter That the acceptance filed I&D we payments
of adjusted is do $XXX per currently for As to future we new of I&D a $XXX we'll as this result, available. an in date and per $X.XX $X.XX was data well rate to in increase in earnings. plan adjusted diluted an diluted This second result tax filing income year-over-year EBITDA debt. or by compared program foreign Non-GAAP quarter have XXXX partially expense was was offset to related a with higher compared million million the share the increase benefit updated a related second our share, as interest The as in of evaluate or XXXX. net not income development quarter variable with net the
I both to was net said third quarter, we made earnings up our the on to the of last figure ratio X increases our our on of it XX-month have to weakens, a business development immediately Turning I ultimately well where as Reiterating through calls, translated balance on comments close sheet. a trues support an Slide start debt ratio that of is investments when This function on we've net XX. at the year. because on impact our see would debt as calculation upward ending that euro-denominated the that made XXXX, the EBITDA leverage strategy our pressure leverage trailing the dollar our value it
XX. at flow. a to our cash closer provide Slide look We Turning
back others, and are in instance, be of incentives As $XXX generated among $XXX year, capital this half a year reminder, about That it There timing of in the that million use. year in in half. use for of working accruals, of The to then and releasing few certain we annual include half related, biggest cash the cash over our represented are the that a includes to we million that working first expect absorbing capital. capital in flow the which, XXXX, second cash follow the we in half items expect pattern. of the same that first working annual and just XX% is
planned the of to the growth build to and HADLIMA first use portfolio. rates to inventory the across about the $XXX support biosimilars target launch million of cash half There's business, including a fill achieve related
reflect In on and of labor foreign inputs. addition, our exchange as the inflation purchased cycles both inventory turns, the impact material and replenishment raw
XX And tracking believe metric of DSO working to second about which June. this outstanding by during that of million driven ticked year, second back trade the should improve alone revert of days if sales noted days quarter. DSO, you're strong about our by probably And was capital or the norm up $XXX days in our We about half the X month of you sales the will half. we in largely trade by that
that unwind to half before fair working the this in trending a implementation $XXX of single-instance of of onetime of of completion cash is logical our of SAP XXXX. of some scheduled the which annual the costs in related will ERP So is there stand-alone in with free costs for an flow the on costs towards are cash use our will related very of and biggest back us which bit for transaction capital XXXX. largest IT that $X spinoff levers the drive billion and that approximately are system, systems first use second Onetime for the half, line about basis XXXX full stand-alone million to year expectation component quarter and single global separation the
drive as manufacturing for productivity. that to PP&E and as capabilities of to deploy infrastructure and CapEx as to good well internal for forecasting purposes, cost remains ahead, a X% we Looking revenue range our technology help efficiency our into capital packaging of continue X%
on Slide now guidance revenue to XX. Turning
the expected headwind a difference biggest the to bridge and this or an revenue our point XX basis based on dynamic an moving impact, to to the on last about $XXX FX guidance an on is approximate are year-on-year. rates Here, XX spot today. slide We're $XX from Compared translation $X our representing change to impact is update, million that $XX we where FX approximate basis improving. of million points high XXX end impact million headwind with
generics foreign movements $X.XX our for impact impact in consistent to for seen adjusting $X.XX the recent a to far in $XX guidance NuvaRing, primarily billion, we've in $XX of continuing in million Atozet States. impact to market NuvaRing to by billion we're XXXX to we revenue XXXX year, LOE year so related Japan United following for related exchange. full as Accordingly, been is generic In range an and approximate minimal in well expect the continued half has LOE the $X.XX possible with $X.XX from that as billion billion, U.S. the to still the of DULERA in erosion year-end. generic of entrant competition second the million the for
million implementation well bridge now HYZAAR to for We expect will in the as in VBP mostly Round July, be improvement be to XXXX of X quarter. impact $XXX The in REMERON which in in the driven from EZETROL's the inclusion November as include annual an million, our and showed X impact $XXX the will last we range from VBP by recent the Organon, Round XXXX implementation products. of
of erosion our fertility estimate commercial our about brands, is NEXPLANON This price access to $XXX my earlier to comment $XX exposure around which and but million raising strategies estimate. million, in biosimilars. previous for is than and to $XXX potential tied U.S. million established to We're rather higher about less expanding
to to million million growth continue from and guidance brands. growth as our unchanged volume biosimilars, expect in Jada fertility, prior from as approximately of pillars: contributions from that NEXPLANON China with growth established multiple $XXX retail, We well coming XXXX, $XXX
of on components guidance Moving other Slide XX. the to
a to of gross back product growth the range. And should This profit margins as franchise U.S. in what adjusted margin biosimilars is from model, in look HADLIMA share gross We be half primarily to to be the margin due saw of gross unfavorable that expect the to continue in franchise launch to fact, line. the operates we the much in mid-XX% quarter. like low- XXXX will mix, the second so
that our sales will out second position first spending bit percentage a than the consistent we R&D a quarter operating half of for and expectations half laid but typically, of are inflationary we SG&A for business remainder the expenses, tends the in we the what full to our future persist OpEx trend year for reflect the the it and of higher growth, as quarter pressures On year. add second in ranges Additionally, our with XXXX. for through last would continued cost the saw as investment
are the Operationally, in no we are financial expect, all we $XX longer beginning with the of our million with year. the largely adjusted of to in the that guidance the we guidance remainder point end of of back out year, bottom about IP line our EBITDA X.X new raising Consistent R&D laid the XX.X% by these of view XX%. is the at percentage so range ranges
to below We some the line. EBITDA also expect net favorability have
favorability we annual Fed's tax expense rate results estimate guidance our million estimate $XX Given due the increased to in that's estimate for our the a offset represent solid execution expectations for but of about of XXXX. hikes, are recent year. $XX on against we had summary, year.
In full non-GAAP depreciation the million by million interest lowering represents the rate by quarter in about most second by in tax the basis rate our decrease savings which of quarter, and XXX our points, We second our $XX of net
answers. relatively dollars of dollar, in let's which for bodes U.S. our performance results U.S. U.S. in that, strength currency to upcoming alignment deliver the performance forward stronger we're the our local terms continue looking We're in near-term well to currencies.
With questions see launch aligned of the over call turn businesses now with as closer the the results and moderation of results Our starting and XACIATO.
Also HADLIMA's our in constant to between launch to the in long-range reported U.S. reported as important, from targets. well
